Blog - Boardroom Buzz

Lofty Pops Launches at Milwaukee County Zoo, Expanding Better-for-You Frozen Treat Options for Wisconsin Families

Featured

-

May 18, 2026

Lofty Pops Launches at Milwaukee County Zoo, Expanding Better-for-You Frozen Treat Options for Wisconsin Families

Lofty Pops, a handcrafted ice pop company, is bringing its better-for-you frozen treats to the Milwaukee County Zoo for the 2026 season, marking its official debut in the Milwaukee market.

Lofty Pops are chef-developed and handcrafted with real fruit and organic ingredients, free from artificial colors and flavors. Each pop is dairy-free, gluten-free and allergen-friendly, with completely plastic-free, home compostable packaging—supporting Milwaukee County Zoo’s broader sustainability initiatives while offering families a premium frozen treat option that meets growing demand for clean-label concessions.

“Our goal is to modernize frozen concessions by delivering a product that reflects how families eat today,” said Natalie Heiter, co-founder and chief marketing officer of Lofty Pops. “We’re excited to introduce Lofty Pops to families visiting Milwaukee County Zoo and to become part of their summer traditions.”

Milwaukee County Zoo guests can find Lofty Pops at the Snack Barn and in the gift shop located in the U.S. Bank Gathering Place.

Milwaukee’s growing focus on family-friendly attractions and quality food experiences makes it a strong market for Lofty Pops’ continued expansion. As more consumers seek out clean-label and allergen-conscious options, the brand brings a modern approach to frozen concessions at one of the region’s most visited destinations.

Lofty Pops offers a rotating lineup of fruit-forward flavors, including Strawberry Lemon, Orange Dreamsicle, Ginger Lime, Blue Razzberry and more.

As Lofty Pops continues to expand, the company is focused on strategic growth across zoos, amusement venues and regional attractions, with plans for continued Midwest expansion in 2026.

Get a taste of Lofty Pops this summer at the Milwaukee County Zoo located at 10001 W. Bluemound Rd., Milwaukee, WI 53226. Visit www.loftypops.com to learn more.

About Lofty Pops
Lofty Pops is a handcrafted ice pop brand founded by a brother-and-sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-crafted using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit https://www.loftypops.com or follow @eatloftypops on social media.

PumasAI Named Clinical Pharmacology & Pharmacometrics Innovator of the Year 2026 by Global Health & Pharma News

Staff Writer

-

May 11, 2026

0

PumasAI Named Clinical Pharmacology & Pharmacometrics Innovator of the Year 2026 by Global Health & Pharma News

Third consecutive recognition from GHP highlights PumasAI’s continued leadership in AI-powered drug development technology

PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that it has been named Clinical Pharmacology & Pharmacometrics Innovator of the Year 2026 by Global Health & Pharma (GHP) News as part of its annual Healthcare and Pharmaceutical Awards program. The recognition marks the third consecutive year that PumasAI has been honored by GHP, following its recognition as Best Clinical Pharmacology Tech Innovator in 2025 and prior recognition in 2024.

Global Health & Pharma’s annual awards program recognizes organizations making meaningful contributions across healthcare and pharmaceuticals through innovation, measurable business performance, and impact on patient outcomes. According to GHP News, winners are selected through an independent, merit-led research process led by the publication’s expert judging team. The organization evaluates both publicly available information and materials submitted by nominees while assessing factors such as innovation, industry contribution, sustained growth, diversification, customer feedback, and measurable advancements within healthcare and pharmaceuticals.

“I am consistently proud of the pace of innovation that our team continues to drive across clinical pharmacology and pharmacometrics,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “Over the past year, we have introduced technologies that are helping scientific teams move faster, automate repetitive work through AI, and make better decisions during critical stages of drug development. We are proud to build tools that create meaningful advantages for our customers and help bring therapies to patients faster.”

Over the past year, PumasAI has continued to expand its technology ecosystem with major advancements across AI, machine learning, and model-informed drug development, including:

The launch of PumasAide, an integrated AI assistant that connects coding agents directly to live Pumas sessions, allowing scientists to generate code, automate analyses, and accelerate modeling workflows in real time.
A partnership with SOPHAS (Society of Pharmacometrics and Health Analytics) to launch a new course aimed at empowering the next generation of scientists and healthcare professionals with practical knowledge on Artificial Intelligence in Drug Development (AIDD).
The release of Pumas 2.8 to embed AI capabilities through PumasAide alongside next-generation estimation methods such as Monte Carlo Expectation Maximization (MCEM), Variational Expectation Maximization (VEM), and new modeling functionality that allows pharmaceutical and biotech teams to perform more advanced analyses within a single integrated platform.

Today, more than 1,400 scientists across 260 institutions use PumasAI tools globally, with free access available to academic institutions to help support the next generation of innovators.

“Our team continues to challenge how work has traditionally been done in this field,” added Ivaturi. “We believe clinical pharmacology and pharmacometrics teams deserve modern technology built for the speed and complexity of today’s development environment. That mindset continues to shape every product and service we bring to market.”

Global Health & Pharma is part of AI Global Media, a UK-based publishing group that has produced more than 200 publications since 2010. The publication’s quarterly digital magazine reaches a highly engaged audience and continues to add thousands of new opt-in subscribers each quarter.

Learn more about PumasAI’s innovations in clinical pharmacology and pharmacometrics at https://pumas.ai/.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.

For additional information, visit www.pumas.ai

Pharma AI Expert Zach Weingarden of TrialAssure Named a 2026 Crain’s Detroit Business Notable Leader in Health Care

Staff Writer

-

May 5, 2026

0

Pharma AI Expert Zach Weingarden of TrialAssure Named a 2026 Crain’s Detroit Business Notable Leader in Health Care

TrialAssure, an award-winning global provider advancing clinical trial transparency, disclosure, and data sharing, announced today that Zach Weingarden, Director of AI Technology and Applications, has been named a 2026 Notable Leader in Health Care by Crain’s Detroit Business. The annual recognition honors Southeast Michigan leaders who are helping shape the future of healthcare through innovation, research, operational excellence, and measurable community impact.

For more than 15 years, Weingarden has worked at the intersection of healthcare, technology, and pharmaceutical innovation, helping solve one of drug development’s biggest operational challenges — turning complex clinical data into faster, clearer, and more compliant pathways to patients.

At TrialAssure, Weingarden leads the development and deployment of AI-driven solutions that help pharmaceutical companies accelerate clinical trial registration, results disclosure, document anonymization, redaction, and generative medical writing workflows. His work helps pharmaceutical and biotechnology companies reduce delays, as well as improve transparency and patient privacy across the clinical development lifecycle.

One of his most significant recent achievements was helping secure a USPTO patent for TrialAssure’s date-offset anonymization technology, which protects patient privacy while preserving the scientific value of clinical data. The innovation is helping organizations respond to growing global transparency requirements while enabling researchers, regulators, and healthcare stakeholders to access critical information faster.

His work has also contributed to major advancements in AI-assisted medical writing, including helping global pharmaceutical companies accelerate Clinical Study Report (CSR), Patient Narrative, Informed Consent Form (ICF), and other document development timelines and modernize workflows that have often slowed drug approvals.

“Healthcare innovation should ultimately create better outcomes for patients, and that starts by removing friction from the systems that support drug development,” said Weingarden. “If we can help researchers share data faster, protect patient privacy more effectively, and reduce delays in clinical documentation, we help move promising therapies closer to the people who need them. That mission keeps me motivated every day.”

Weingarden is also a recognized thought leader in healthcare AI and regulatory innovation. He regularly speaks at major industry events including PHUSE and Regulatory Affairs Professionals Society (RAPS), contributes thought leadership to industry publications, and serves in the PHUSE Data Transparency Working Group, helping shape best practices across the global pharmaceutical sector.

“Zach understands how to bridge innovation with real-world healthcare challenges,” said Prasad M. Koppolu, COO of TrialAssure. “He has helped build technology that improves transparency, strengthens privacy protections, and removes inefficiencies that can slow progress in medicine. His leadership continues to create meaningful impact across healthcare, and we’re proud to see his leadership in the space continue to grow.”

Honorees are selected through peer nominations and an in-depth editorial review. To connect with Zach and other leaders at TrialAssure, visit https://trialassure.com/about/leadership/.

TSRL Contributes to New Publication Highlighting Promising Antibacterial Candidate for Resistant Hospital Infections

Staff Writer

-

May 5, 2026

0

TSRL Contributes to New Publication Highlighting Promising Antibacterial Candidate for Resistant Hospital Infections

TSRL, Inc., a preclinical CRO specializing in drug delivery & PK/ADME testing services and early-stage development strategies, today announced its contribution to a newly published study in Microbiology Spectrum by the American Society of Microbiology (ASM) evaluating the in vitro activity of MRS-2541, a novel methionyl-tRNA synthetase inhibitor designed to target serious gram-positive hospital infections. Additionally, it follows a 2024 publication in Antimicrobial Agents and Chemotherapy on the same lead candidate.

The new publication, titled “In vitro activity of MRS-2541, a novel MetRS inhibitor, against a selection of resistant gram-positive organisms associated with serious hospital infections,” highlights the growing need for new antibacterial agents capable of addressing resistant pathogens in clinical settings.

MRS-2541 demonstrated strong activity across a broad panel of gram-positive organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-intermediate strains. In multiple comparisons, the compound showed greater potency than widely used antibiotics such as vancomycin, linezolid, and daptomycin. The study also reported strong activity against Enterococcus faecalis and Enterococcus faecium, including vancomycin-resistant strains, further supporting its potential as a future therapeutic option.

“These findings reinforce the importance of continued innovation in antibacterial research,” said Dr. Elke Lipka, President and CEO of TSRL and board member of the Preclinical Drug Development Platform (PCDDP) at North-West University in South Africa. “Programs like this require a clear understanding of compound behavior, careful study design, and the ability to translate data into meaningful development decisions. That is where experienced preclinical teams can make a real difference.”

Performed in collaboration with the University of Washington, the study highlights TSRL’s role in supporting early-stage programs that address complex therapeutic challenges. Through integrated capabilities in bioanalysis, formulation development, pharmacokinetics, and toxicology, TSRL works with biotech, pharmaceutical, and academic partners to advance promising compounds toward clinical readiness.

As antibiotic resistance continues to rise globally, the identification and development of new treatment options remain a priority for researchers and healthcare providers alike. The results from this study support further investigation of MRS-2541 as a potential option for serious infections caused by resistant gram-positive bacteria.

Frederick S. Buckner, MD, Professor in the Department of Medicine, Division of Allergy & Infectious Diseases at the University of Washington School of Medicine, said, “TSRL will make an outstanding team to bring forward much needed therapeutics to combat the spreading problem of multi-drug resistant infectious diseases.”

Read the full publication here: https://journals.asm.org/doi/full/10.1128/spectrum.03615-25#con1

Lofty Pops Returns to Toledo Zoo for 2026 Season, Expanding Access to Better-for-You Frozen Treats

Featured

Staff Writer

-

May 4, 2026

0

Lofty Pops Returns to Toledo Zoo for 2026 Season, Expanding Access to Better-for-You Frozen Treats

Lofty Pops, a handcrafted ice pop company, is returning to the Toledo Zoo for the 2026 summer season, marking its second year at one of northwest Ohio’s premier family destinations.

Lofty Pops are chef-developed and handcrafted with real fruit and organic ingredients, free from artificial colors and flavors. Each pop is dairy-free, gluten-free and allergen-friendly, with completely plastic-free, home compostable packaging — supporting Toledo Zoo’s broader sustainability initiatives while offering families a premium frozen treat option that meets growing demand for clean-label concessions.

“Our goal is to modernize frozen concessions by delivering a product that reflects how families eat today,” said Natalie Heiter, co-founder and chief marketing officer of Lofty Pops. “We’re thrilled for a second summer at Toledo Zoo.”

Toledo Zoo guests can find Lofty Pops in Monarch Marketplace and at the Northern Ice Way Station.

As a longstanding family destination in northwest Ohio, the Toledo region continues to prioritize accessible, family-friendly experiences. Lofty Pops’ presence at the Toledo Zoo enhances concession offerings with a better-for-you option that meets the needs of today’s families while complementing the Zoo’s focus on quality visitor experiences.

Lofty Pops offers a rotating lineup of fruit-forward flavors, including Strawberry Lemon, Orange Dreamsicle, Piña Colada, Dino Pop, Blue Razzberry, Chocolate Fudge, and more.

As Lofty Pops continues to expand, the company is focused on strategic growth across zoos, amusement venues and regional attractions, with plans for continued Midwest expansion in 2026.

Get a taste of Lofty Pops this season at the Toledo Zoo located at 2 Hippo Way, Toledo, OH 43609. Visit www.loftypops.com to learn more.
About Lofty Pops
Lofty Pops is a handcrafted ice pop brand founded by a brother-and-sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-created using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit https://www.loftypops.com or follow @eatloftypops on social media.

Lofty Pops Debuts at Henry Vilas Zoo, Bringing Better-for-You Frozen Treats to Madison Families

Featured

Staff Writer

-

May 4, 2026

0

Lofty Pops Debuts at Henry Vilas Zoo, Bringing Better-for-You Frozen Treats to Madison Families

Lofty Pops, a handcrafted ice pop company, is now offering its better-for-you frozen treats at the Henry Vilas Zoo for the 2026 season, marking its official debut in the Madison, Wisconsin market.

Lofty Pops products are handcrafted with real fruit and organic ingredients, with no artificial colors or flavors. Each pop is dairy-free, gluten-free and allergen-friendly, with completely plastic-free, home compostable packaging — supporting Henry Vilas Zoo’s broader sustainability initiatives while offering families a premium frozen treat option that meets growing demand for clean-label concessions.

“Our goal is to modernize frozen concessions by delivering a product that reflects how families eat today,” said Natalie Heiter, co-founder and chief marketing officer of Lofty Pops. “We’re excited to introduce Lofty Pops to families visiting Henry Vilas Zoo and to become part of their summer traditions.”

Henry Vilas Zoo guests can find Lofty Pops at the Glacier Grille and at Base Camp.

Known for its strong emphasis on health, sustainability and community-driven values, the Madison area is an ideal fit for Lofty Pops’ clean-label approach. The brand’s focus on organic ingredients and allergen-friendly offerings aligns with the expectations of local families seeking higher-quality food options at a trusted community destination.

Lofty Pops offers a rotating lineup of fruit-forward flavors, including Strawberry Lemon, Orange Dreamsicle, Piña Colada, Blue Razzberry and more.

As Lofty Pops continues to expand, the company is focused on strategic growth across zoos, amusement venues and regional attractions, with plans for continued Midwest expansion in 2026.

Get a taste of Lofty Pops this summer at Henry Vilas Zoo located at 702 S Randall Ave, Madison, WI 53715. Visit www.loftypops.com to learn more.
About Lofty Pops
Lofty Pops is a handcrafted ice pop brand founded by a brother-and-sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-created using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit https://www.loftypops.com or follow @eatloftypops on social media.

SW North America Builds CNC Machining Momentum with Strategic Sales and Engineering Expansion Across Western and Central Regions

Staff Writer

-

April 27, 2026

0

SW North America Builds CNC Machining Momentum with Strategic Sales and Engineering Expansion Across Western and Central Regions

SW North America, a leading supplier of horizontal multi- and single-spindle CNC machining centers, automation, and complete system solutions, today announced the western and central expansion of its North American team with multiple new hires and internal promotions, showing a clear signal of the company’s accelerated growth and commitment to serving manufacturers across the entire United States.

Key leaders that have recently joined or been promoted within SW include the following:

Chuck Duckworth joins SW North America as Regional Sales Manager, covering Wisconsin, Iowa, Illinois, and Missouri. In this role, Duckworth will work closely with customers to deliver smart CNC machining solutions tailored to their specific manufacturing challenges.
Creed Hayes comes on board as Regional Sales Manager for Texas, Oklahoma, and New Mexico. Hayes will help manufacturers across the region advance and optimize their production processes through SW’s advanced machining technology.
Marco Kozina has been promoted to Regional Sales Manager, now overseeing Washington, Oregon, California, Nevada, and Arizona. Kozina’s promotion recognizes his contributions to the team and positions SW North America for continued success in a strategically important and growing western territory.

In addition to strengthening its sales and service leadership, the company has expanded its team with the addition of engineers, operations specialists, program managers, and service professionals. These strategic hires ensure the organization is well positioned to support increasing demand for customer service while successfully executing a growing number of new projects.

“Growth like this means greater support for our customers, the manufacturers of American made products that are integral to numerous industries, like medical, automotive, aerospace, agriculture, and many others,” said Andrew Rowley, General Sales Manager with SW North America. “These leaders showcase our dedication to building the right team to meet the evolving needs of today’s leading manufacturers in every region we serve.”

These recent additions to our leadership and support teams bring deep industry expertise and regional knowledge that will enhance SW North America’s ability to serve customers across the full lifecycle of their CNC machining investments, from initial consultation and system design to long-term support. Other recent highlights in SW’s growth include the following:

Introduction of new machining technology such as the BF 12-21D twin-spindle machining center, designed for high-speed production of structural aluminum components.
Expansion of automation solutions, including the modular Mobile S-Cell robot cell, which enables flexible, scalable automation across machining, washing, assembly, and logistics stations.
Continued investment in digital manufacturing tools and turnkey system solutions, helping customers optimize production through plant simulation, integrated automation, and advanced multi-spindle CNC machining platforms.

Learn more about SW’s full North American offerings at https://sw-machines.com/us/products/.

About SW North America

SW North America is a subsidiary of Schwäbische Werkzeugmaschinen GmbH, a leading international manufacturer of smart manufacturing solutions. With its North American headquarters in Michigan, SW is the world market leader in multi-spindle CNC machining centers for cutting a variety of materials in the automotive, electromobility, agricultural and construction machinery, medical technology, and aerospace industries.

SW currently has more than 1,700 employees across its global headquarters in Schramberg-Waldmössingen, Germany, and locations in China, France, Hungary, Mexico, Poland, and the United States. The company achieved a group turnover of $535 million in 2022.

Learn more about SW North America at https://sw-machines.com/us/.

Cliniphai Named “Startup of the Year” for its Athena Platform as Gold Stevie® Award in The 24th Annual American Business Awards®

Staff Writer

-

April 23, 2026

0

Cliniphai Named “Startup of the Year” for its Athena Platform as Gold Stevie® Award in The 24th Annual American Business Awards®

Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announced that its flagship platform, Athena, has been named a Gold Stevie® Award winner in The 24th Annual American Business Awards®. The company was recognized in the Startup of the Year – Business Product Industries category for introducing the first marketplace platform built specifically for regulated clinical translation.

The American Business Awards are one of the premier business awards programs in the United States, recognizing organizations and products that demonstrate innovation, growth, and market impact. Due to receiving high average scores from judges, Athena earned the program’s highest recognition level.

“From the beginning, our team has believed that clinical translation needed a complete operational rethink,” said Jason Martin, MS, MBA, Co-Founder and Chairman at Cliniphai. “Athena was built to solve one of the most overlooked bottlenecks in global clinical research, and we are honored to see that innovation recognized on a national stage.”

Athena was originally launched to streamline clinical translation and localization workflows. The platform has since evolved into a marketplace model that connects Sponsors, CROs, eCOA providers, translation experts, and reviewers in a centralized environment designed to improve speed, transparency, and compliance.

“I am proud to share this honor with our dedicated team of hard-working individuals across the globe as we work to meet the growing demand for smarter infrastructure in clinical research,” said Vladimir Mats, PhD, Co-Founder and CEO at Cliniphai. “Our goal has always been simple. Help life sciences companies move faster, communicate better, and bring important therapies to patients without unnecessary delays.”

Built specifically for regulated industries, Athena helps organizations reduce delays tied to manual translation workflows while improving visibility across global projects. The platform supports AI-assisted translation, human-in-the-loop review, version tracking, quality assurance checkpoints, and secure collaboration across multilingual clinical studies.

The complete list of Gold, Silver, and Bronze Stevie Award winners by category can be found at https://aba.stevieawards.com/.

To schedule a call to learn more, visit: https://cliniphai.com/contact-us/.

About Cliniphai Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. Its flagship solution, Athena, is a marketplace-driven platform for clinical translation and localization that combines AI-powered workflows with built-in compliance and operational transparency. Designed to support sponsors, eCOA providers, and language experts alike, Athena enables secure, scalable, and collaborative execution across global studies. Cliniphai was honored as a Gold recipient due to its high average scores from judges in the American Business Awards. For more, visit www.cliniphai.com.

TrialAssure Wins “Data Privacy Solution of the Year” for AI-Powered Anonymization and Redaction Platform

Featured

Staff Writer

-

April 16, 2026

0

TrialAssure Wins “Data Privacy Solution of the Year” for AI-Powered Anonymization and Redaction Platform

CANTON, Mich. (April 16, 2026) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that its TrialAssure ANONYMIZE product has been named Data Privacy Solution of the Year in the 2026 Data Breakthrough Awards program. TrialAssure ANONYMIZE supports data sharing and transparency initiatives by automatically identifying sensitive information, applying consistent anonymization rules, and providing full auditability for the pharmaceutical and biotechnology industry.

The annual Data Breakthrough Awards recognize the world’s most innovative data technology companies. The 2026 program received more than 3,500 nominations globally, making this year’s selection process highly competitive. Winners across categories included leading organizations such as Box, Fivetran, Grafana, Hitachi Vantara, MongoDB, NetApp, Comcast, ADP, and other global data technology innovators.

“We’re honored to receive this recognition in such a competitive global field,” said Prasad M. Koppolu, COO of TrialAssure. “This award highlights the strength of our anonymization and redaction technology and the innovation behind TrialAssure ANONYMIZE. Our goal has always been to help organizations share data responsibly through a scientific lens, and this recognition reinforces the importance of that mission.”

The Data Breakthrough Awards program recognizes companies and technologies that are transforming the data landscape through innovation, performance, and real-world impact. TrialAssure’s selection underscores its leadership in privacy-focused AI solutions for the life sciences industry.

Strong growth in anonymization and redaction

Recently, TrialAssure was granted a utility patent by the United States Patent and Trademark Office (USPTO) for its proprietary date offset anonymization method that enhances data protection by streamlining the anonymization of subject-level dates in clinical trial documents.

Key strengths of the platform include:

AI-guided automation backed by expert oversight to streamline redaction and anonymization of clinical documents and datasets
Support for global data sharing requirements, including EMA Policy 0070, Health Canada PRCI, EU CTR, and others
Centralized, real-time workbench that improves reviewer collaboration, decision tracking, and audit readiness
Transparent risk scoring and traceability that give users full visibility into decisions, offsets, and anonymized elements
Seamless integration with clinical trial disclosure workflows to reduce rework and increase submission efficiency
Use beyond pharma, in legal, finance, and transportation applications, among others

To learn more about TrialAssure ANONYMIZE, visit: https://trialassure.com/software/anonymize/

ABOUT TRIALASSURE

TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure is a multi-year winner in the Data Breakthrough Awards as “Solution of the Year.”

For more information, visit www.trialassure.com.

Lofty Pops Earns USDA Organic Certification, Expanding Clean CPG Frozen Treat Options Nationwide

Featured

Staff Writer

-

April 15, 2026

0

Lofty Pops Earns USDA Organic Certification, Expanding Clean CPG Frozen Treat Options Nationwide

Lofty Pops, a Michigan-based handcrafted ice pop company, today announced it has officially achieved U.S. Department of Agriculture (USDA) Organic certification, with third-party certification through Quality Assurance International (QAI), an NSF company, marking a major milestone as the brand accelerates its expansion in the frozen treats CPG markets.

Lofty Pops are crafted with real fruit and organic ingredients, with no artificial colors or flavors. Each pop is dairy-free, gluten-free, and allergen-friendly, offering a premium frozen treat option that aligns with growing consumer demand for clean-label products. The brand also features plastic-free, home compostable packaging, extending its commitment to thoughtful, responsible product design beyond ingredients.

“The USDA Organic certification sets the standard for what Lofty Pops stands for, and we’re proud to achieve it at this stage,” said Natalie Heiter, co-founder and chief marketing officer of Lofty Pops. “Families are asking better questions about what they eat, and we’ve built a product that answers them. This is how frozen treats should be made.”

The announcement comes as Lofty Pops enters a pivotal growth phase, expanding across high-traffic family destinations while building momentum toward broader retail and grocery opportunities. Lofty Pops is now available for the full 2026 season at the Detroit Zoo, Toledo Zoo and Brookfield Zoo Chicago, with additional expansion to Henry Vilas Zoo in Madison, Wisconsin, the Milwaukee County Zoo, and more to be announced. For retail locations, visit www.loftypops.com/locations to find a store near you.

Demand for organic is on the rise

It’s been noted that nearly 6 out of 10 people think that it is important for their purchased food to be natural or organic, and more than 75 percent said they purchased organic foods within the last six months (Acosta Group).

This increasing demand for better-for-you frozen treats in both venue-based and retail environments come at a time when consumers seek products that align with their values across ingredients, sourcing, and packaging.

“Better ingredients should be the baseline, not the exception,” said Heiter. “This is the future of frozen treats.”

Lofty Pops offers a rotating lineup of fruit-forward flavors, including:

Fruit Punch
Strawberry Lemon
Orange Dreamsicle
Piña Colada
Banana Pudding
Dino Pop
Blue Razzberry
Chocolate Fudge

Get a taste of Lofty Pops near you, and visit www.loftypops.com to find locations or start a partnership conversation.

About Lofty Pops
Lofty Pops is a Michigan-based handcrafted ice pop brand founded by a brother-and-sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-crafted using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching at the Detroit Zoo in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit https://www.loftypops.com or follow @eatloftypops on social media.

NewsWeekPRO

Boardroom Buzz

Boardroom Buzz

About us

Company

The latest

Subscribe